# EDGAR Filing Document

**Accession Number:** 0001577524
**File Stem:** 0001140361-23-002125
**Filing Date:** 2023-1
**Character Count:** 15522
**Document Hash:** 5d9acebb1ab3d6998685651d47d7d557
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-23-002125.hdr.sgml**: 20230119

**ACCESSION NUMBER**: 0001140361-23-002125

**CONFORMED SUBMISSION TYPE**: SC 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230119

**DATE AS OF CHANGE**: 20230119

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AMARIN CORP PLC\UK
- **CENTRAL INDEX KEY:** 0000897448
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-52399
- **FILM NUMBER:** 23537421

**BUSINESS ADDRESS:**
- **STREET 1:** SPACES SOUTH DOCKLANDS, BLOCK C
- **STREET 2:** 77 SIR JOHN ROGERSON'S QUAY
- **CITY:** DUBLIN 2
- **STATE:** L2
- **ZIP:** D02 VK60
- **BUSINESS PHONE:** 353 1 6699 020

**MAIL ADDRESS:**
- **STREET 1:** SPACES SOUTH DOCKLANDS, BLOCK C
- **STREET 2:** 77 SIR JOHN ROGERSON'S QUAY
- **CITY:** DUBLIN 2
- **STATE:** L2
- **ZIP:** D02 VK60

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMARIN PHARMACEUTICALS PLC
- **DATE OF NAME CHANGE:** 20000201

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ETHICAL HOLDINGS PLC
- **DATE OF NAME CHANGE:** 19930322
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sarissa Capital Management LP
- **CENTRAL INDEX KEY:** 0001577524
- **IRS NUMBER:** 900924432
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 660 STEAMBOAT ROAD
- **CITY:** GREENWICH
- **STATE:** CT
- **ZIP:** 06830
- **BUSINESS PHONE:** 203-302-2330

**MAIL ADDRESS:**
- **STREET 1:** 660 STEAMBOAT ROAD
- **CITY:** GREENWICH
- **STATE:** CT
- **ZIP:** 06830

------

**UNITED STATES**<br> **SECURITIES AND EXCHANGE COMMISSION**<br> Washington, D.C. 20549

### SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 5)\*<br>

---

| |
|:---|
| Amarin Corporation plc |
| (Name of Issuer) |
| Ordinary Shares, par value 50 pence per share |
| (Title of Class of Securities) |
| 023111206 |
| (CUSIP Number) |
| Mark DiPaolo<br> Senior Partner, General Counsel<br> Sarissa Capital Management LP<br> 660 Steamboat Road<br> Greenwich, CT 06830<br> 203-302-2330 |
| (Name, Address and Telephone Number of Person<br> Authorized to Receive Notices and Communications) |
| January 18, 2023 |
| (Date of Event which Requires Filing of this Statement) |

---

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

------

CUSIP No. 023111206 Page 2 of 4 Pages <br> SCHEDULE 13D

This Amendment No. 5 to Schedule 13D ("Amendment No. 5") relates to American Depositary Shares ("ADS(s)"), each ADS representing one ordinary share, par value 50 pence per share (the "Ordinary Shares"), issued by Amarin Corporation plc, a company incorporated under the laws of England and Wales (the "Issuer"), and amends the initial statement on Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on January 24, 2022 (the "Initial Schedule 13D"), as amended by Amendment No. 1 to Schedule 13D filed on June 3, 2022, Amendment No. 2 to Schedule 13D filed on June 16, 2022, Amendment No. 3 to Schedule 13D filed on October 11, 2022 and Amendment No. 4 to Schedule 13D filed on January 11, 2023 (the Initial Schedule 13D as so amended, the "Schedule 13D"). All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.

This Amendment No. 5 is being filed to amend Item 4 and Item 7 as follows:

**Item 4. Purpose of Transaction.** Item 4 of the Schedule 13D is hereby amended to include the following:

On January 18, 2023, Sarissa Capital issued the press release attached as Exhibit 8 hereto.<br>

**Item 7. Material to Be Filed as Exhibits.** Item 7 of the Schedule 13D is hereby amended to include the following:

Exhibit 8 – Press Release, January 18, 2023

------

CUSIP No. 023111206 Page 3 of 4 Pages <br> SCHEDULE 13D

#### SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: January 18, 2023

---

| | |
|:---|:---|
| SARISSA CAPITAL MANAGEMENT LP | SARISSA CAPITAL MANAGEMENT LP |
| By: | /s/ Mark DiPaolo |
|  | Name: Mark DiPaolo |
|  | Title: Senior Partner, General Counsel |

---

---

| |
|:---|
| /s/ Alexander J. Denner |
| Alexander J. Denner |
| /s/ Louis Sterling III |
| Louis Sterling III |

---

------

CUSIP No. 023111206 Page 4 of 4 Pages <br> SCHEDULE 13D

#### <br>

#### INDEX TO EXHIBITS

Exhibit 1 – Joint Filing Agreement of the Reporting Persons\*

Exhibit 2 – Press Release, June 15, 2022\*

Exhibit 3 – Press Release, October 11, 2022\*

Exhibit 4 – Requisition Notice, January 10, 2023\*

Exhibit 5 – Press Release, January 10, 2023\*

Exhibit 6 – Joint Filing Agreement of the Reporting Persons\*

Exhibit 7 – Power of Attorney Granted by Louis Sterling III in favor of Mark DiPaolo and Patrice Bonfiglio, January 10, 2023\*

[Exhibit 8](ny20006859x3_ex-8.htm) – Press Release, January 18, 2023

\* Previously filed.

------

## Exhibit 99.8

------

**EXHIBIT 8**<br>

Sarissa Capital Calls Out Amarin's Sham Board Refreshment

Sarissa puts little faith in Chairman Per Wold-Olsen's board refreshment process that resulted in NO SHAREHOLDER

REPRESENTATIVES ON THE BOARD

Sarissa believes the board's refusal to consider shareholder input on the board despite Amarin's failures indicates the current board

does not prioritize interests of shareholders

Greenwich, CT, January 18, 2023 – Sarissa Capital Management LP ("Sarissa") today made the following statement on Amarin Corporation plc (NASDAQ: AMRN):

In 2022 alone, Amarin stock lost over two-thirds of its value, and shareholders lost over $840 million in equity.\* The European launch is behind schedule, reimbursement in Germany (typically one of the largest markets in Europe) appears imperiled, and spending mismanagement has weakened the cash coffers. Yet the board has the audacity to state publicly, "the Company made solid progress in 2022, against its strategic objectives." To shareholders, the owners of the company, these statements are gravely concerning because they reflect a total lack of understanding of events and the mission of the board and management – to maximize value for shareholders. To do so, the company must not destroy value.

Indeed, Amarin has repeatedly overpromised and underdelivered. Below are three of many examples.

&nbsp;&nbsp;&nbsp;&nbsp;• Vascepa is a great drug with the potential to have a meaningful impact on society. However, since the label expansion for cardiovascular risk reduction, Amarin stock has lost over 90% of its value.<sup>†</sup>

&nbsp;&nbsp;&nbsp;&nbsp;• Last year, management committed to launching in up to six key European markets and obtain pricing and reimbursement approval in up to eight European markets in 2022. They launched and secured positive pricing and reimbursement
 decisions in only five European markets. In addition, despite the novel drug's ability to reduce cardiovascular events and its significant potential to reduce a country's healthcare costs, Amarin could not secure reimbursement approval in
 Germany, a historically top revenue generating country for pharmaceuticals in Europe.

&nbsp;&nbsp;&nbsp;&nbsp;• Amarin's slow, reactive responses to changing market dynamics have destroyed significant shareholder capital. An alarming example from 2022 is Amarin's slow response to the US launch of a third generic in January 2022 that quickly and
 meaningfully reduced sales via both price and volume. Instead of having a plan ready to enact immediately in response to the long anticipated generic risk, Amarin waited six months, until June 2022, to announce a major reduction in
 expenses. In that time, significant shareholder capital – and additional credibility of management and the board – were destroyed.

In June 2022, shareholders loudly expressed their lack of faith in the board and management at the shareholder meeting. Shareholders such as ourselves share the concern, among many concerns, that the current management and board will continue to overpromise and underdeliver and destroy shareholder capital, mismanage expenses, run out of money and massively dilute existing shareholders.

Characterizing the board's interaction with Sarissa as "in good faith" is a gross misrepresentation of the facts. The board, led by Chairman Per Wold-Olsen, showed no sense of urgency in interviewing shareholder candidates for the board and took fifteen weeks to interview three Sarissa candidates. A few of the directors acknowledged following Chairman Per Wold-Olsen's lead and that the time to interview directors was unnecessarily lengthy. His insistence on a lengthy process confused the duration with quality of process, and ultimately the board rejected adding any shareholder representatives to the board in favor of their own candidates. Shareholders are the owners of the company with a vested interest in the company's success. Yet the board is devoid of any shareholder representatives.

------

Sarissa is Amarin's largest shareholder and has a history of creating significant shareholder value in healthcare companies, including those with cardiovascular drugs such as The Medicines Company. We can only conclude that Amarin's board does not seek real change and instead wants to remain entrenched at the expense of shareholders.

As detailed in our previous press release<sup>††</sup>, Sarissa has submitted notice to Amarin to call a special meeting to remove Chairman Per Wold-Olsen from the board and add 7 directors to the board. In accordance with UK law, Amarin has up to 21 days to call the special meeting, which must be held within 28 days of calling the special meeting. We are asking all shareholders to remain engaged and voice their opinions by voting at the special meeting.

Many shareholders have reached out asking us how to vote at the special meeting, and we will provide instructions in the coming weeks and ahead of the meeting.

\*Calculated between Dec 31, 2021, and Dec 30, 2022, Bloomberg

<sup>†</sup>Calculated between Dec 13, 2019, and Jan 13, 2023, Bloomberg

<sup>††</sup>Press release link: <u>https://www.businesswire.com/news/home/20230109005938/en/Sarissa-Capital-Submits-Notice-to-Call-a-Special-Meeting-of-Amarin-Shareholders-to-Add-Directors-and-Remove-Chairman-Per-Wold-Olsen</u> <br>

###

*CERTAIN INFORMATION CONCERNING THE PARTICIPANTS*

** 

<br> Sarissa Capital Management LP ("Sarissa Capital"), together with the other participants named herein (collectively, "Sarissa"), intends to file a preliminary proxy statement and accompanying proxy card with the Securities and Exchange Commission ("SEC") to be used to solicit votes for the election of its slate of highly-qualified nominees as directors of Amarin Corporation plc (NASDAQ: AMRN) (the "Company"), at a special meeting of shareholders of the Company. SARISSA STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEB SITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS' PROXY SOLICITOR, THE IDENTITY AND CONTACT INFORMATION FOR WHICH WILL BE SET FORTH IN THE PROXY STATEMENT THAT WILL BE MADE AVAILABLE TO SHAREHOLDERS.

------

The participants in the proxy solicitation are anticipated to include Sarissa Capital, Sarissa Capital Offshore Master Fund LP ("Offshore"), Sarissa Capital Master Fund II LP ("Master II"), Sarissa Capital Athena Offshore Fund Ltd ("Athena"), Sarissa Capital Catapult Fund LLC ("Catapult"), Sarissa Capital Hawkeye Fund LP ("Hawkeye"), ISP Fund LP ("ISP"), Atom Master Fund LP ("Atom"), Sarissa Capital Management GP LLC ("Management GP"), Sarissa Capital Offshore Fund GP LLC ("Offshore GP"), Sarissa Capital Fund GP LP ("Fund GP LP"), Sarissa Capital Fund GP LLC ("Fund GP LLC"), Dr. Alexander J. Denner, Patrice Bonfiglio, Dr. Paul Cohen, Mark DiPaolo, Keith L. Horn, Odysseas Kostas, Louis Sterling III and Diane E. Sullivan.

As of the date hereof and subject to the further explanatory information set forth in this paragraph, funds and other investment vehicles affiliated with Sarissa Capital and Dr. Denner may be deemed to beneficially own, within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), 25,210,000 ordinary shares, par value 50 pence per share, of the Company (the "Shares"), as more fully described below. In addition, as of the date hereof, Mr. Sterling may be deemed to separately beneficially own, within the meaning of Rule 13d-3 under the Exchange Act, 117,772 Shares. Given Mr. Sterling's beneficial ownership of Shares, he and the funds and other investment vehicles affiliated with Sarissa Capital and Dr. Denner may be deemed to have formed a group within the meaning of Rule 13d-5(b) under the Exchange Act. The number of Shares stated herein that may be deemed to be beneficially owned by Mr. Sterling does not include Shares that may be deemed to be beneficially owned by such funds and other investment vehicles, and the number of Shares stated herein that may be deemed to be beneficially owned by such funds and other investment vehicles does not include Shares that may be deemed to be beneficially owned by Mr. Sterling. Subject to the preceding sentence, as of the date hereof, the number of Shares that may be deemed to be beneficially owned, within the meaning of Rule 13d-3 under the Exchange Act, by funds and other investment vehicles affiliated with Sarissa Capital and Dr. Denner is as follows:

---

| | |
|:---|:---|
| Sarissa Capital | 25,210,000 |
| Offshore | 6,188,100 |
| Master II | 342,600 |
| Athena | 3,164,000 |
| Catapult | 4,298,200 |
| Hawkeye | 3,928,800 |
| ISP | 6,663,377 |
| Atom | 624,923 |
| Management GP | 25,210,000 |
| Offshore GP | 9,694,700 |
| Fund GP LP | 17,921,700 |
| Fund GP LLC | 17,921,700 |
| Dr. Denner | 25,210,000 |

---

Contact: Jean Puong<br> Sarissa Capital Management LP<br> info@sarissacap.com

------